In the 2016 U.S. election, cannabis legalization measures passed in eight out of nine voting states. Now as the 2020 election approaches, many Americans are hoping for another big win.
This November, voters in five states will decide whether to adopt new medical cannabis laws, recreation laws, or both.
Currently, medical cannabis use is legal in 33 states, and 11 of those states have legalized it for recreational use.
If more states legalize some form of cannabis use, it could mean a huge opportunity for industry growth. Cannabis supporters believe legalization in more states could have a domino effect on other states, particularly those looking to address budgetary and social justice issues
In 2019, cannabis sales in legal states totaled about $15 billion. By 2024, the number is expected to top $30 billion.
The five states to vote on cannabis legalization
In 2016, 51% of voters said no to legalize recreational cannabis.
According to estimates from industry publication Marijuana Business Daily, recreational sales in Arizona could total $700 million to $760 million by 2024.
Governor Phil Murphy vowed to legalize cannabis when he was elected back in 2017. This has unfortunately been proven to be a tough task.
If voters decide on it, the bill known as Public Question No. 1, would legalize cannabis use for adults 21 and older.
Currently, all medical and recreational cannabis use is banned in South Dakota. If the bill passes, South Dakota could enact medical and recreational programs in one fell swoop.
Montana voters will see two cannabis initiatives on their ballots in November.
Ballot issue I-190 would allow adults in the state to possess, buy and use cannabis for recreational use. A separate initiative, CI-118, would establish 21 as the legal age to purchase, possess and consume cannabis.
Mississippi voters are facing two competing measures to legalize medical cannabis. Initiative 65 would allow doctors to recommend medical cannabis to patients with any one of 22 qualifying medical conditions, such as cancer and MS.
The competing measure requires that medical cannabis products are up to par with pharmaceutical qualities, and limits the smoking of cannabis to those who are terminally ill.